Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Zhou, Dong; Feng, Jihua; Zhang, Jianfeng

doi:10.1016/j.clinthera.2022.09.012

Cited by 8 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A more recent systematic review and meta-analysis by Dong et al that compared Ideg as an intervention against other longacting basal insulin analogs (insulin glargine (Igla-100 and Igla-300) and insulin detemir, collectively) revealed overall comparable reduction in HbA1c and severe hypoglycemia between the two groups (22). FPG, overall, and nocturnal hypoglycemia, were significantly lower with Ideg in the combined group of type 1 and type 2 diabetes patients (22). However, the review by Dong et al had many limitations.…”

Section: Importance Of the Current Reviewmentioning

confidence: 99%

Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

Alhmoud,

Saad,

Omar

2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundUltra-long-acting insulin analogs [insulin degludec (IDeg) and insulin glargine 300 units/mL (IGla-300)] offer a longer duration of action with less risk of hypoglycemia compared to other long-acting insulins. However, data about the comparative efficacy and safety are inconsistent.MethodsWe searched CENTRAL, PubMed, Embase, ICTRP Search Portal, and ClinicalTrials.gov on 7 October 2022. Randomized controlled trials (RCTs) comparing the safety and efficacy of IDeg (100 or 200 units/mL) and IGla-300 in patients with type 1 or type 2 diabetes were included. Three review authors independently selected trials, assessed the risk of bias, extracted data, and evaluated the overall certainty of the evidence using GRADE. The primary outcomes were the change in glycated hemoglobin (HbA1c) and any hypoglycemia; the secondary outcomes were the change in fasting plasma glucose (FPG) and severe and nocturnal hypoglycemia.ResultsFour open-label RCTs were included (2727 participants), 3 parallel and 1 cross-over. Overall, the risk of bias assessment yielded some concern or high risk. There was a comparable change in HbA1c from baseline to the end of treatment, a mean difference of 0.07% (95% confidence interval (CI) 0.06 – 0.19; p = 0.29; 3 trials; 2652 patients; very low-certainty evidence), and a comparable rate of any hypoglycemia, rate ratio 1.02 (95% CI 0.8 – 1.3; p = 0.87; 3 trials; 2881 patients; very low-certainty evidence). IDeg resulted in more reduction in FPG compared to IGla-300, mean difference of 10.27 mg/dL (95% CI 7.25 – 13.29; p < 0.001; 3 trials; 2668 patients; low-certainty evidence). Similar rates of nocturnal and severe hypoglycemia were observed, rate ratio of 1.13 (95% CI 0.72 – 1.78; p = 0.54; 3 trials; 2668 patients; very low-certainty evidence) and 1.4 (95% CI 0.41 – 4.73; p = 0.59; 2 trials; 1952 patients; very low-certainty evidence), respectively.ConclusionThere is no evidence of a difference between IDeg and IGla-300 in the mean change in HbA1c and the risk of anytime, nocturnal, and severe hypoglycemia. IDeg appeared to cause a higher reduction in FPG compared to IGla-300. However, this finding should be interpreted with caution due to the small number of trials included and their high risk of bias.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022364891, identifier CRD42022364891.

show abstract

Section: Importance Of the Current Reviewmentioning

confidence: 99%

Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

Alhmoud,

Saad,

Omar

2024

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Most of the food we consume is converted by the body into sugar (glucose), which is then released into the bloodstream [ 45 ]. Excessive blood sugar in the bloodstream can lead to major health issues such as heart disease, sight loss, and renal illness if cells resist insulin response [ 46 , 47 ]. Type 1 diabetes is reported to affect 5–10% of the population, while type 2 diabetes affects about 90–95% of the population, making it one of the biggest threats in the world [ 48 ].…”

Section: Biological Activitiesmentioning

confidence: 99%

Therapeutic Potential of Pectin and Its Derivatives in Chronic Diseases

Dambuza,

Rungqu,

Oyedeji

et al. 2024

Molecules

View full text Add to dashboard Cite

Non-communicable diseases (NCDs) are described as a collection of chronic diseases that do not typically develop from an acute infection, have long-term health effects, and frequently require ongoing care and therapy. These diseases include heart disease, stroke, cancer, chronic lung disease, neurological diseases, osteoporosis, mental health disorders, etc. Known synthetic drugs for the treatment or prevention of NCDs become increasingly dangerous over time and pose high risks due to side effects such as hallucination, heart attack, liver failure, etc. As a result, scientists have had to look for other alternatives that are natural products and that are known to be less detrimental and contain useful bioactive compounds. The increasing understanding of the biological and pharmacological significance of carbohydrates has helped to raise awareness of their importance in living systems and medicine, given they play numerous biological roles. For example, pectin has been identified as a class of secondary metabolites found in medicinal plants that may play a significant role in the treatment and management of a variety of NCDs. Pectin is mainly made of homogalacturonan, which is a linear polymer composed primarily of D-galacturonic acid units (at least 65%) linked in a chain by α-(1,4)-glycosidic linkages. There are also modified pectins or derivatives that improve pectin’s bioavailability. Pectin is found in the cell walls of higher plants (pteridophytes, angiosperms, and gymnosperms), particularly in the middle lamella of the plant material. Citrus pectin is used in various industries. This article compiles information that has been available for years about the therapeutic importance of pectin in chronic diseases, different modes of pectin extraction, the chemistry of pectin, and the potency of pectin and its derivatives.

show abstract

“…There have been significant advancements in the treatment of type 1 diabetes (T1D) with the implementation of new insulin formulations and technologies associated with improved glycaemic control. [1][2][3][4][5] Despite the growing use of these new therapeutic tools, data from the T1D Exchange Registry and international diabetes registries still show that a minority of patients with T1D are able to achieve recommended glycaemic targets. [6][7][8] Many patients experience partial clinical remission, characterised by improved glycaemic control and lower exogenous insulin requirements due to temporary recovery in beta-cell function.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Muscle‐to‐fat ratio in children and adolescents with type 1 diabetes in predicting glycaemic control and partial clinical remission

Averbuch,

Yackobovitch‐Gavan,

Ben Simon

et al. 2024

Diabetes Metabolism Res

View full text Add to dashboard Cite

BackgroundAdvances in treatment could mitigate the expected adverse changes in the body composition of children and adolescents with type 1 diabetes (T1D).ObjectivesTo examine the evolution of weight status and body composition and their association with glycaemic control and partial clinical remission in youth with T1D.MethodsNinety‐nine participants with T1D (median age 9.5 years [interquartile range 7.3, 12.9], 59.6% boys) were longitudinally followed for 3 years since diagnosis. Data at seven pre‐determined time points were extracted from medical files. Outcome measures included body mass index (BMI) z‐scores, muscle‐to‐fat ratio (MFR) z‐scores, haemoglobin A1c (HbA1c) levels, continuous glucose monitoring metrics, and insulin dose‐adjusted HbA1c (IDAA1c) levels.ResultsThe BMI z‐scores increased significantly (p < 0.001) for both sexes, with no significant change in MFR z‐scores over time. The girls had higher BMI z‐scores (p < 0.001) and lower MFR z‐scores than the boys (p = 0.016). The mean HbA1c levels decreased during the first month and at 3 months since diagnosis (p < 0.001), then plateaued and achieved a median overall HbA1c of 7.1% for the entire cohort. At 12 months, 37 participants (37.6%) were in partial clinical remission, as evidenced by IDAA1c ≤ 9. The odds of partial clinical remission at 2 years increased by 2.1‐fold for each standard deviation increase in the MFR z‐score (p < 0.001). Higher MFR z‐scores were associated with better metabolic control.ConclusionsIntegration of body composition assessments could mitigate adverse body changes in paediatric patients with T1D.

show abstract

Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis

Cited by 8 publications

References 30 publications

Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

Therapeutic Potential of Pectin and Its Derivatives in Chronic Diseases

Muscle‐to‐fat ratio in children and adolescents with type 1 diabetes in predicting glycaemic control and partial clinical remission

Contact Info

Product

Resources

About